Antibiotics have transformed modern medicine. They are essential for treating infectious
diseases and enable vital therapies and procedures. However, despite this success, their …

Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …

Antibacterial resistance is one of the greatest threats to human health. The development of
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …

Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Despite a significant decline in deaths in children younger than 5 years globally in the past
three decades, preventable and treatable infectious diseases remain the leading cause of …

β-lactam antibiotics are one of the most widely used and diverse classes of antimicrobial
agents for treating both Gram-negative and Gram-positive bacterial infections. The β-lactam …

Beta-lactam antibiotics remain one of the most commonly prescribed drug classes, but they
are limited by their propensity to cause hypersensitivity reactions (eg, from allergy to …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …